Qiagen NV

Type: Company
Name: Qiagen NV
Nationality: Netherlands
Web Address: http://www.qiagen.com/
Fact Sheet: Fact Sheet for Qiagen NV
First reported 3 hours ago - Updated 3 hours ago - 1 reports

Biotech backer LSP banks $100M to fund a new generation of startups

European venture outfit LSP (Life Sciences Partners) has raised $100 million toward a new biotech fund, setting out to stake a dozen or so innovators in drugs, devices and diagnostics.The latest raise is the close in LSP's planned $190 million 5th fund, ... [Published FierceBiotech - 3 hours ago]
First reported 4 hours ago - Updated 4 hours ago - 2 reports

miRNA Services Market to Grow at a CAGR of 14% over the Next Five Years

Noida, UP -- (SBWIRE) -- 10/01/2014 -- Numerous miRNA players such as Qiagen, Life Technologies and Exiqon are offering miRNA based services using their proprietary technologies. These services span across the complete miRNA research process including ... [Published CEOWorld Magazine - 4 hours ago]
First reported 7 hours ago - Updated 7 hours ago - 1 reports

Qiagen (QGEN) Showing Support Near $22.48

The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on Qiagen NV (QGEN) that includes 9% downside protection. Sell one contract of the May. '15 $22.50 call ... [Published MarketIntelligenceCenter.com - 7 hours ago]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Qiagen NV’s “Neutral” Rating Reaffirmed at Zacks (QGEN)

Zacks restated their neutral rating on shares of Qiagen NV (NASDAQ:QGEN) in a research note issued to investors on Thursday. The firm currently has a $25.00 price target on the stock. Zacks’ analyst wrote, “Qiagen reported second-quarter 2014 results ... [Published Mideast Time - Sep 29 2014]
Entities: Qiagen NV, NASDAQ
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

New study confirms superior sensitivity of digene HC2 HPV DNA Test vs. the other FDA-approved tests for HPV

Ratings require JavaScript to be enabled.A recently published study comparing three FDA-approved screening tests for human papillomavirus (HPV) provides the latest confirmation of superior sensitivity for QIAGEN's digene HC2 HPV DNA Test. HPV is the primary ... [Published Medical News Today - Sep 29 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Qiagen's Molecular Diagnostics, Global Market Show Strength

On Sep 25, we issued an updated research report on Qiagen N.V. ( QGEN - Analyst Report ) – a leading provider of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. Qiagen once again posted in-line results ... [Published Zacks.com - Sep 26 2014]
First reported Sep 25 2014 - Updated Sep 26 2014 - 2 reports

Qiagen's Digene HPV test shows benefits in new study

:08 in Scientific Company News Qiagen has highlighted data from a new study showing the superior sensitivity benefits of its Digene Hybrid Capture 2 human papillomavirus (HPV) DNA Test. The recently published research from the Mayo Clinic compared three ... [Published Zenopa - Sep 26 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

New tools to assist KWS

A German company has donated a machine to the Kenya Wildlife Service to be used in genetics and forensic laboratory.Speaking while receiving automated nucleic acid extraction machine from Qiagen at the KWS headquarters, Nairobi, director William Kiprono ... [Published The Star (Kenya) - Sep 26 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 1 reports

Volume Spike Detected in Shares of QIAGE...

QIAGEN shares are trading on heavy volume today, having fallen 1.9% to $23.28. Today's volume of 861,000 shares tops the average 30-day volume of 587,000 shares. Unusually high volume can signify a potential turning point or validate a breakout.QIAGEN ... [Published Financial News Network online - Sep 25 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 2 reports

Qiagen NV Earns “Neutral” Rating from Zacks (QGEN)

Zacks’ analyst wrote, “Qiagen reported second-quarter 2014 results with adjusted EPS of $0.25, which increased 4.2% year over year but was in line with the Zacks Consensus Estimate. Adjusted net sales were up 4% at CER to $331.2 million, also in line ... [Published American Banking News - Forex - Sep 25 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 1 reports

The United States Market For In Vitro Diagnostic Tests: 2014 Report

DUBLINThe United StatesMarket sizes, forecasts and shares are provided, as well as a geographic breakdown of the segments, where possible. Changes in technology development, regulatory and reimbursement issues, clinical care, and business environments ... [Published TheStreet.com - Sep 25 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 1 reports

KENYA TO USE FORENSIC EQUIPMENT TO FIGHT POACHING

By Judith AkoloNAIROBI, Sept 25 (NNN-KBC) -- The Kenya Wildlife Service (KWS) has turned to using scientific evidence in cases involving wildlife crime, says its Acting Director, William Kiprono.Speaking when he received some of the equipment needed for ... [Published NAM News Network - Sep 25 2014]

Quotes

"RNA Analysis/Transcriptomics Market by Technology (Microarray, PCR, NGS, RNAi), by Application (Clinical Diagnostics, Drug Discovery, Toxicogenomics), by End-User (Academic Research, Pharmaceutical and Biotech Companies) - Global Forecast to 2019" research report is now available with ReportsnReports.com. Companies like Affymetrix Inc. (U S ), Agilent Technologies Inc...
"There's a lot of interest in identification and validation of novel biomarkers that may represent potential drug targets or may lead to novel diagnostic tests" said Bruce Carlson
Mirko Holzer, CEO and co-founder of the company together with Sven Schäfer, explains: "There are a number of competitors in each of our market areas, but none connects the fields of application using a single, holistic solution - a decisive feature for medium and large customers. We believe that with BrandMaker, we can contribute to the excellent reputation that 'Business software, made in Germany' enjoys across the globe."
Dr. Patricia Braly, a nationally recognized gynecologic oncologist at Women's Cancer Care in Covington, Louisiana, commented: "Sensitivity is the key in selecting an HPV test, because the goal of screening is to rule out HPV disease with a high level of confidence - and to identify patients in need of more evaluation and treatment. With the time between screenings now extending to five years for many women, we cannot afford the risk of 'false negatives' that miss patients who may have CIN 2+ disease - or even cervical cancer. This is why my clinic relies on examination and co-testing with the Pap smear and digene HPV Test to protect our patients."

More Content

All (310) | News (183) | Reports (1) | Blogs (90) | Audio/Video (0) | Fact Sheets (3) | Press Releases (33)
sort by: Date | Relevance
Biotech backer LSP banks $100M to fund a new ge... [Published FierceBiotech - 3 hours ago]
miRNA Services Market to Grow at a CAGR of 14% ... [Published CEOWorld Magazine - 4 hours ago]
miRNA Services Market to Grow at a CAGR of 14% ... [Published SBWire - 4 hours ago]
Qiagen (QGEN) Showing Support Near $22.48 [Published MarketIntelligenceCenter.com - 7 hours ago]
Protein Expression Market by Products, Applicat... [Published Individual.com - 11 hours ago]
Global Specialty Enzymes Industry [Published Finwin - 23 hours ago]
LSP garners $100 mln for new fund [Published PE Hub Blog - Sep 30 2014]
LSP raises EUR 80 mln to invest in medical inno... [Published Tornado Insider - Sep 30 2014]
Global Laboratory Filtration Market To See 7.0%... [Published Reliance Trust - Sep 30 2014]
"GeneFluidics Inc. - Product Pipeline Analysis,... [Published SBWire - Sep 30 2014]
Report: Race For Proteomics Knowledge Spurs Inv... [Published TheStreet.com - Sep 30 2014]
Report: Race for Proteomics Knowledge Spurs Inv... [Published Scottrade - Sep 30 2014]
Potential Qiagen (QGEN) Trade Has 9.13% Downsid... [Published MarketIntelligenceCenter.com - Sep 30 2014]
Needed: Expanded RAS Mutation Analysis for Pred... [Published Oncology Times - Sep 30 2014]
Qiagen NV’s “Neutral” Rating Reaffirmed at Zack... [Published Mideast Time - Sep 29 2014]
BrandMaker prepares for further growth [Published The Marketing Site - Sep 29 2014]
Market Report, "BioProtect Ltd. - Product Pipel... [Published SBWire - Sep 29 2014]
Qiagen (QGEN) Showing Bearish Technicals With R... [Published MarketIntelligenceCenter.com - Sep 29 2014]
New study confirms superior sensitivity of dige... [Published Medical News Today - Sep 29 2014]
Biggest Movers in Healthcare Stocks Now – CMN E... [Published InvestorPlace.com - Sep 26 2014]
Qiagen's Molecular Diagnostics, Global Market S... [Published Zacks.com - Sep 26 2014]
Qiagen's Digene HPV test shows benefits in new ... [Published Zenopa - Sep 26 2014]
RNA Analysis/Transcriptomics Market Worth $3,77... [Published TheStreet.com - Sep 26 2014]
"Oxford Gene Technology - Product Pipeline Anal... [Published SBWire - Sep 26 2014]
New Market Research Report: Bonovo Orthopedics,... [Published SBWire - Sep 26 2014]
Qiagen (QGEN) Trading Near $22.87 Support Level [Published MarketIntelligenceCenter.com - Sep 26 2014]
Global Next-Generation Sequencing Trends [Published Individual.com - Sep 26 2014]
Iressa blood test nears approval in Europe [Published PMLive - Sep 26 2014]
New tools to assist KWS [Published The Star (Kenya) - Sep 26 2014]
Recombinant attenuated dengue viruses comprisin... [Published PharmCast - Sep 26 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Qiagen (QGEN) Showing Support Near $22.48 [Published MarketIntelligenceCenter.com - 7 hours ago]
The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on Qiagen NV (QGEN) that includes 9% downside protection. Sell one contract of the May. '15 $22.50 call ...
LSP garners $100 mln for new fund [Published PE Hub Blog - Sep 30 2014]
LSP said Tuesday that it has raised $100 million in the first close of its new fund LSP 5. The target is $150 million. Its LPs include unnamed institutional and private investors from Europe and the U.S. The pool will focus on emerging private medical ...
Potential Qiagen (QGEN) Trade Has 9.13% Downsid... [Published MarketIntelligenceCenter.com - Sep 30 2014]
After Monday’s trading in Qiagen NV (QGEN) the algorithms behind MarketIntelligenceCenter.com's Artifical Intelligence Center picked out a trade that offers a 7.71% or 12.39% (for comparison purposes only), while providing 9.13% downside protection. The ...
Qiagen (QGEN) Showing Bearish Technicals With R... [Published MarketIntelligenceCenter.com - Sep 29 2014]
For a hedged play on Qiagen NV (QGEN), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the May. '15 $22.50 covered call for a net debit in the $20.99 area. That is also the break-even stock price for the covered call. This trade ...
Qiagen (QGEN) Trading Near $22.87 Support Level [Published MarketIntelligenceCenter.com - Sep 26 2014]
After Thursday’s trading in Qiagen NV (QGEN) the option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center uncovered a trade that offers a 7.45% return, or 11.77% annualized (for comparison purposes only), ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Acquisitions News - Sep 22 2014]
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Acquisitions News - Sep 22 2014]
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Acquisitions News - Sep 16 2014]
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Advertising News - Sep 03 2014]
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Acquisitions News - Aug 25 2014]
1 2 3 4 5 6 7
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.